A Comparison between Radiolabeled Fluorodeoxyglucose Uptake and Hyperpolarized 13C-Labeled Pyruvate Utilization as Methods for Detecting Tumor Response to Treatment

Increased frequency of endometrial cancer (EC) since the beginning of this century exceeds that of breast cancer and to a large extent can be attributed to dynamics of parameters, which characterize hormonal and metabolic status of ill women and molecular genetic landscape of transforming endometrium. During the past few years there are suggested several options for a personalized assessment of the risk of EC. The aim of this article is to propose and justify own version of this score with the idea of its further not only retrospective but also prospective testing both in relation to the risk of developing endometrial cancer as well as an additional marker helping to predict tumor response to treatment.

Download Full-text

Micronuclei Assay — A Predictive Variable for Tumor Response to Treatment

Advances in Experimental Medicine and Biology - Consensus on Hyperthermia for the 1990s ◽

10.1007/978-1-4684-5766-7_5 ◽

1990 ◽

pp. 51-55 ◽

Cited By ~ 5

Author(s):

Homayoon Shidnia ◽

William Crabtree ◽

Ned Hornback ◽

Peter Young ◽

Mary Hartson ◽

...

Keyword(s):

Tumor Response ◽

Response To Treatment ◽

Predictive Variable ◽

Micronuclei Assay

Download Full-text

Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations

Radiographics ◽

10.1148/rg.282075068 ◽

2008 ◽

Vol 28 (2) ◽

pp. 329-344 ◽

Cited By ~ 161

Author(s):

Chikako Suzuki ◽

Hans Jacobsson ◽

Thomas Hatschek ◽

Michael R. Torkzad ◽

Katarina Bodén ◽

...

Keyword(s):

Tumor Response ◽

Response To Treatment

Download Full-text

Response to Treatment Series: Part 1 and Introduction, Measuring Tumor Response—Challenges in the Era of Molecular Medicine

American Journal of Roentgenology ◽

10.2214/ajr.11.7083 ◽

2011 ◽

Vol 197 (1) ◽

pp. 15-17 ◽

Cited By ~ 9

Author(s):

Daniel C. Sullivan ◽

Constantine Gatsonis

Keyword(s):

Tumor Response ◽

Molecular Medicine ◽

Response To Treatment

Download Full-text

The role of the neoadjuvant approach in the treatment of primary operable HER2 positive breast cancer

Malignant tumours ◽

10.18027/2224-5057-2020-10-2-4 ◽

2020 ◽

Vol 10 (2) ◽

pp. 45-52

Author(s):

M. A. Frolova ◽

Е. V. Glazkova ◽

A. V. Petrovsky ◽

О. V. Krokhina ◽

M. В. Stenina ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Response ◽

Residual Tumor ◽

Response To Treatment ◽

Comprehensive Treatment ◽

Her2 Positive ◽

Ki 67 ◽

Her2 Positive Breast Cancer ◽

Neoadjuvant Systemic Therapy ◽

Positive Breast Cancer

Neoadjuvant systemic therapy is an essential component of the comprehensive treatment of primary operable HER2‑positive breast cancer. Therefore, it is extremely important to search for treatment efficacy predictors and optimal system for assessing tumor response to treatment. The study analyzed factors predicting pathological complete response (pCR) in patients with luminal and non‑luminal HER2‑positive tumor subtypes. The morphological assessment of the tumor response to treatment was carried out using the RCB system; additional characteristics of the residual tumor were studied as well. It was shown that a comprehensive assessment involving the use of the RCB system and determination of the Ki ‑ 67 level helps to divide patients into prognostic groups and individualize the adjuvant therapy plan.

Download Full-text

The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy

Oncology Reports ◽

10.3892/or.2018.6299 ◽

2018 ◽

Cited By ~ 1

Author(s):

Susanna Nuvoli ◽

Sarah Galassi ◽

Ilaria Gelo ◽

Gaia Rocchitta ◽

Alessandroï¿½ Fancellu ◽

...

Keyword(s):

Neoadjuvant Therapy ◽

Breast Imaging ◽

Tumor Response ◽

Residual Tumor ◽

Response To Treatment ◽

Molecular Breast Imaging ◽

Tumor Extent ◽

Complete Tumor

Download Full-text

EXTH-46. MRS BASED BIOMARKERS OF IDH1 MUTANT GLIOMA RESPONSE TO THE IDH INHIBITOR BAY-1436032

Neuro-Oncology ◽

10.1093/neuonc/noab196.685 ◽

2021 ◽

Vol 23 (Supplement_6) ◽

pp. vi173-vi173

Author(s):

Donghyun Hong ◽

Noriaki Minami ◽

Céline Taglang ◽

Georgios Batsios ◽

Anne Marie Gillespie ◽

...

Keyword(s):

Animal Models ◽

Animal Studies ◽

Response To Treatment ◽

Resonance Spectroscopy ◽

Low Grade ◽

Isocitrate Dehydrogenase 1 ◽

1H Mrs ◽

Hyperpolarized 13C ◽

13C Mrs ◽

Mutant Idh1

Abstract Gliomas are the most prevalent type of brain tumor in the central nervous system. Mutations in the cytosolic enzyme isocitrate dehydrogenase 1 (IDH1) are a common feature of primary low-grade gliomas, catalyzing the conversion of α-ketoglutarate (αKG) to the oncometabolite 2-hydroxyglutarate (2HG), and mutant IDH1 is a therapeutic target for these tumors. Several mutant IDH inhibitors are currently in clinical trials, nonetheless, complementary non-invasive early biomarkers to assess drug delivery and potential therapeutic response are still needed. The goal of this study was therefore to determine the potential of 1H and hyperpolarized 13C magnetic resonance spectroscopy (MRS)-based biomarkers as indicators of mutant IDH1 low-grade glioma response to treatment with the clinically-relevant IDH1 inhibitor BAY-1436032 in cells and animal models. Immortalized human astrocytes engineered to express mutant IDH1 were treated with 500nM (IC50 value) of BAY-1436032 and BT257 tumors implanted in rats were treated with 150mg/kg of BAY-1436032. To assess steady-state metabolite levels, 1H MRS spectra were acquired on a 500 MHz MRS cancer for cells and a 3 T scanner for animal studies. To assess metabolic fluxes, we used hyperpolarized 13C MRS and probed the fate of hyperpolarized [1-13C]αKG. 1H MRS showed a significant decrease in 2HG as well as a significant increase in glutamate (Glu) and phosphocholine (PCh) following BAY-1436032 treatment in both cell and animal models compared to controls. Furthermore, hyperpolarized 13C MRS showed that hyperpolarized 2HG production from hyperpolarized [1-13C]αKG was decreased and hyperpolarized glutamate production from hyperpolarized [1-13C]αKG was increased in the BAY-1436032 treated groups compared to controls. These findings are consistent with our previous study, which investigated the MRS-detectable consequences of two other mutant IDH inhibitors: AG120 and AG881. Collectively, our work identifies translatable MRS-based metabolic biomarkers of mutant IDH1 inhibition.

Download Full-text

Pediatric Rhabdomyosarcomas: Three-Dimensional Radiological Assessments after Induction Chemotherapy Predict Survival Better than One-Dimensional and Two-Dimensional Measurements

Cancers ◽

10.3390/cancers12123808 ◽

2020 ◽

Vol 12 (12) ◽

pp. 3808

Author(s):

Giovanna Orsatti ◽

Carlo Morosi ◽

Chiara Giraudo ◽

Alessia Varotto ◽

Filippo Crimì ◽

...

Keyword(s):

Tumor Response ◽

World Health ◽

Response To Treatment ◽

Significant Prognostic Factor ◽

Kaplan Meier ◽

Maximal Diameter ◽

Radiological Response ◽

Early Tumor Response ◽

Early Tumor ◽

Better Than

Radiological response to neoadjuvant chemotherapy is currently used to assess the efficacy of treatment in pediatric patients with rhabdomyosarcoma (RMS), but the association between early tumor response on imaging and survival is still controversial. The aim of this study was to investigate the prognostic value of assessing radiological response after induction therapy in pediatric RMS, comparing four different methods. This retrospective, two-center study was conducted on 66 non-metastatic RMS patients. Two radiologists measured tumor size on pre- and post-treatment magnetic resonance (MR) or computed tomography (CT) images using four methods: considering maximal diameter with the 1D-RECIST (Response Evaluation Criteria in Solid Tumors); multiplying the two maximal diameters with the 2D-WHO (World Health Organization); multiplying the three maximal diameters with the 3D-EpSSG (European pediatric Soft tissue sarcoma Study Group); obtaining a software-assisted volume assessment with the 3D-Osirix. Each patient was classified as a responder or non-responder based on the proposed thresholds for each method. Tumor response was compared with survival using Kaplan–Meier plots, the log-rank test, and Cox’s regression. Agreement between methods and observers (weighted-κ) was also calculated. The 5-year event-free survival (5yr-EFS) calculated with the Kaplan–Meier plots was significantly longer for responders than for non-responders with all the methods, but the 3D assessments differentiated between the two groups better than the 1D-RECIST or 2D-WHO (p1D-RECIST = 0.018, p2D-WHO = 0.007, p3D-EpSSG and p3D-Osirix < 0.0001). Comparing the 5yr-EFS of responders and non-responders also produced adjusted hazard ratios of 3.57 (p = 0.0158) for the 1D-RECIST, 5.05 for the 2D-WHO (p = 0.0042), 14.40 for the 3D-EpSSG (p < 0.0001) and 11.60 for the 3D-Osirix (p < 0.0001), indicating that the volumetric measurements were significantly more strongly associated with EFS. Inter-method agreement was excellent between the 3D-EpSSG and the 3D-Osirix (κ = 0.98), and moderate for the other comparisons (0.5 < κ < 0.8). The 1D-RECIST and the 2D-WHO tended to underestimate response to treatment. Inter-observer agreement was excellent with all methods (κ > 0.8) except for the 2D-WHO (κ = 0.7). In conclusion, early tumor response was confirmed as a significant prognostic factor in RMS, and the 3D-EpSSG and 3D-Osirix methods predicted response to treatment better than the 1D-RECIST or 2D-WHO measurements.

Download Full-text